Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Inserting the gene for interleukin-2 into a person's cancer cells may improve the body's ability to fight cancer. Using Leuvectin to deliver this gene may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of Leuvectin followed by surgery in treating patients who have stage II or stage III prostate cancer.

Key facts

Study ID

NCT00004050

Run by

Vical

People needed

13

Starts

1999-06-01

Expected to finish

2003-04-01

Last updated by the study team

2014-07-29

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.